Portfolio:
in constant progression

At mAbxience we are working to increase patients’ global accessibility.

Highly attractive portfolio targeting the areas of oncology, osteoporosis, rheumatology & psoriasis, and pediatrics.

Quality, safety and efficacy

Biosimilars are equivalent in terms of quality, safety and efficacy to the reference products. mAbxience guarantees the equivalence by subjecting the drugs to exhaustive comparability testing, regulated by the competent authorities. This ensures that our biosimilars are almost identical to the reference product with respect to structure, biological activity and overall performance of the final drug product.

In addition, mAbxience develops clinical trials to meet all the international requirements and of the different regions where it develops its activity.

In December 2014, mAbxience launched its first biosimilar, rituximab, which is now approved and distributed in many markets globally. Our second product, bevacizumab, was launched in the first market in November 2016.